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Abstract: Among the different ways to reduce the secondary effects of antineoplastic drugs in cancer
treatment, the use of nanoparticles has demonstrated good results due to the protection of the
drug and the possibility of releasing compounds to a specific therapeutic target. The α-isoform
of the folate receptor (FR) is overexpressed on a significant number of human cancers; therefore,
folate-targeted crosslinked nanoparticles based on BSA and alginate mixtures and loaded with
paclitaxel (PTX) have been prepared to maximize the proven antineoplastic activity of the drug
against solid tumors. Nanometric-range-sized particles (169 ± 28 nm–296 ± 57 nm), with negative
Z-potential values (between −0.12 ± 0.04 and −94.1± 0.4), were synthesized, and the loaded PTX
(2.63 ± 0.19–3.56 ±0.13 µg PTX/mg Np) was sustainably released for 23 and 27 h. Three cell lines
(MCF-7, MDA-MB-231 and HeLa) were selected to test the efficacy of the folate-targeted PTX-loaded
BSA/ALG nanocarriers. The presence of FR on the cell membrane led to a significantly larger uptake
of BSA/ALG–Fol nanoparticles compared with the equivalent nanoparticles without folic acid on
their surface. The cell viability results demonstrated a cytocompatibility of unloaded nanoparticle–
Fol and a gradual decrease in cell viability after treatment with PTX-loaded nanoparticle–Fol due to
the sustainable PTX release.
Keywords: folate-targeted nanoparticles; BSA/alginate nanocarriers; paclitaxel; cellular uptake;
cell viability
1. Introduction
Targeted treatments and personalized medicine are two of the axes of current oncology.
They refer to the design of drugs that respond specifically to some genetic characteristics of
each patient’s cancer. More efficiency is pursued with fewer adverse effects, adapting the
procedures to the characteristics of each patient. Numerous studies have focused on the
development of targeted drug-delivery systems [1] for cancer treatment in order to reduce
side effects due to the unspecific effect of anticancer drugs on healthy cells. Nanocarriers
based on natural polymers have the advantage of being a priori biocompatible and also
biodegradable. Among biological polymers, polysaccharides have been used for thera-
peutic delivery systems [2] due to their non-toxic and non-reactogenic properties, as well
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as their physicochemical properties that allow chemical modifications and, therefore, an
easy preparation of nanocarriers. Their reactive groups, such as hydroxyl, carboxyl or
amine, can attach different molecules and so introduce new physicochemical characteris-
tics [3]. Anionic polysaccharides have an important role in the preparation of drug delivery
systems [4]; they have extensively contributed to the development of several types of
nanocarriers for cancer treatment and diagnosis. Among anionic polysaccharides, alginate,
whose structure is based on a backbone of [1–4] linked β-D-mannuronic acid (M units)
and α-L-guluronic acid (G units), have been used for preparing different nanocarriers for
biomedical applications in the last years [5]. Alginate has been declared safe by the FDA [6]
for application in humans as a dental impression material or wound dressing, and their
hydrogels are the most assayed material for bone tissue engineering and bioprinting since
they provide an appropriate niche for cell loading [7]. On the other hand, there is significant
interest in developing anticancer drug carriers based on serum albumin [8] due to the thera-
peutic efficacy of Abraxane®, an albumin-bound form of paclitaxel, that rapidly dissociates
in serum, losing some benefits of nanoformulations. Some studies have indicated that
Abraxane® induced the overexpression of P-glycoprotein and did not allow it to overcome
the common small molecule drug resistance problem mediated by P-gp [9]; in addition,
when crosslinked and non-crosslinked PTX-loaded albumin nanoparticles were compared,
differences in pharmacokinetics were observed, due to their different physiological ways
of delivering the drug to the tumor [10]. In an attempt to improve the characteristics of
nanocarriers, numerous studies have focused on the synthesis of nanosystems formed by
proteins and polysaccharides; in this way, core–shell microcapsules based on BSA gel with
a polyelectrolyte complex multilayer shell of hyaluronic acid and chitosan, encapsulating
Sorafenib, have been designed for hepatocellular cancer therapy [11]. Ionic crosslinked
nanoparticles based on chitosan and BSA were also developed as carriers for doxorubicin,
showing their biocompatibility after intravenous administration in a Wistar rat model [12].
Nanocarriers can reach the internal part of solid tumors, taking advantage of their angio-
genesis, but the uptake of these nanosystems improves significantly if they are targeted
to overexpressed receptors on the surface of cancer cells. Among those receptors [13], the
axis folic acid/folate receptor is one of the most important ligand–receptor interactions
used to target cancer. Folic acid reaches normal tissues through two carriers, the reduced
folate carrier (RFC) and the proton-coupled folate transporter, but either of them are able
to bind folate conjugates (such as folate drugs or folate nanocarriers). Folate-bounded
nanocarriers are internalized by the membrane-bound folate receptor (FR), which has a
high affinity for folate (Kd ∼ 0.1–1 nmol/L) although is expressed on few cell types. The
FR-α isoform is overexpressed on 40% of human cancers (such as ovary, kidney, breast and
liver tumors) where it is completely accessible to FA-bounded systems, unlike what hap-
pens in healthy cells, where the FR-α isoform is detected in the apical membrane of some
epithelial cells, where folate conjugates do not have access. This fact makes folate-targeted
nanosystems [14,15] very selective for cancer cells.
In the present study different compositions of folate-targeted nanoparticles based
on BSA and alginate have been prepared for use as an active targeting strategy for the
delivery of paclitaxel (PTX). Thus, the challenge of this study was the preparation of stable
nanoparticles capable of specifically delivering that hydrophobic drug in a prolonged time
in the environment of many solid tumors, avoiding the hypersensitivity, nephrotoxicity
and cardiotoxicity reactions induced by the conventional use of Cremophor®EL [16] and
drug resistance problem mediated by the aforementioned P-gp [9]. These nanoparticles
were in vitro characterized to evaluate their application in targeted tumor therapy.
2. Materials and Methods
2.1. Materials
Folic acid (FA), alginic acid sodium salt (ALG; viscosity 15.00–20.00 cps, 1% H2O),
trypsin from bovine pancreas (13,000 units/mg solid), gentamicin (50 µg/mL), dimethyl
sulfoxide (DMSO), methylthiazoletetrazolium (MTT), 6-coumarin, ethylenediamine (ED;
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98%), N-hydroxysuccinimide (NHS), N,N’-dicyclohexylcarbodiimide (DCC) were pur-
chased from Sigma-Aldrich (Barcelona, Spain). Sodium hydroxide (NaOH), hydrochloric
acid (HCl; 35%), trichloroacetic acid, ethanol absolute, ethylenediaminetetraacetic acid
(EDTA), Tween®80, triethylamine, anhydrous di-sodium hydrogen phosphate (Na2HPO4),
di-hydrogen potassium phosphate (KH2PO4), diethylether, dichloromethane (DCM) and
acetonitrile (HPLC-analysis grade) were supplied by Panreac (Madrid, Spain). Bovine
serum albumin (BSA, Fraction V), sodium chloride (NaCl) and disodium hydrogen phos-
phate dehydrated were purchased from Merck (Barcelona, Spain). Fetal bovine serum
(FBS), penicillin (50 U/mL), streptomycin (50 µg/mL) and 0.05% trypsin/0.53 mM EDTA
were purchased from Invitrogen Life Technologies, Grand Island, NY. Dubecco’s Modified
Eagle Medium was purchased from Lonza Bioscience (Bornem, Belgium). Paclitaxel (Taxol)
was supplied by Tocris Bioscience (Mw 889.95 > 99%). All water used in the assays was
Millipore Milli Q grade.
2.2. Preparation of BSA/ALG Nanoparticles
Folate-targeted nanoparticles (Nps–Fol) based on bovine serum albumin (BSA) and
alginate (ALG) mixtures were prepared and stabilized by amide bonds using ethylenedi-
amine. BSA 5% (w/v) and ALG 1% (w/v) aqueous solutions were prepared in the presence
of EDAC 50 mM (Sigma-Aldrich). Subsequently, several blends of BSA/ALG were obtained
by mixing different volumes of the solutions prepared previously (Supplementary data
Table S1). Ethylenediamine (ED) was added to each blend according to 2:1 ratio (polymer:
ED, w/w) under intense stirring conditions (magnetic stirrer), and pH was then adjusted to
3 with HCl to attain amide bond formation. Stirring was maintained for 2 h and blends
were finally centrifuged (10,000 rpm, 5 min; Sigma SM202 centrifuge). Pellets were freeze
dried (Heto PowerDry LL1500 Freeze Dryer, Thermo Electro Corporation, Waltham, MA,
USA) for 24 h at −110 ◦C.
The conjugation of folate to nanoparticles was carried out by a carbodimiide reaction
with NHS–folate. The N-Hydroxysuccinimide ester of folic acid (NHS–folate) was prepared
according to the method developed by Lee and co-workers [17]. Folic acid (2.5 g) was
dissolved in 50 mL of dry dimethyl sulfoxide (DMSO) plus 1.25 mL of triethylamine and
reacted with NHS (1.3 g) in the presence of dicyclohexylcarbodiimide (2.35 g) overnight
at room temperature. The byproduct, dicyclohexylurea, was removed by filtration. The
DMSO solution was then freeze-dried, and NHS–folate was precipitated in diethylether.
The final product, NHS–folate, was washed several times with anhydrous ether, dried
under vacuum, and yielded a yellow powder.
The conjugation of folate to nanoparticles was carried out following the method
developed by Zhang and co-workers [18]: NHS–folate (50 mg/mL) was dissolved in 3 mL
DMSO and added slowly to 6 mL of the stirred nanoparticle suspension (10 mg NP/mL,
pH adjusted to 10 using 1 M carbonate/bicarbonate buffer). After stirring for 3 h at room
temperature, the reaction mixture was centrifuged (10,000 rpm, 10 min) in order to separate
the folate conjugated nanoparticles from unreacted folic acid and other byproducts and
then washed with DMSO (10,000 rpm, 10 min). Finally, folate-conjugated nanoparticles
(30BSA/70ALG–Fol, 40BSA/60ALG–Fol; 50BSA/50ALG–Fol) were freeze dried for 24 h
at −110 ◦C.
2.3. Characterization of Nanoparticles
2.3.1. Composition of BSA/AlG Nanoparticles
Composition of nanoparticles was determined according to the method developed
by Martinez and co-workers [19]. The composition of BSA/ALG nanoparticles was stud-
ied measuring the concentration of BSA and ALG in the supernatant obtained after the
centrifugation of the samples in the synthesis process. The difference between the initial
concentration of each polymer and their concentration in the supernatant was determined,
to reveal the proportion of each polymer in nanoparticle formation. Concentration of
alginate in the supernatant was determined by measuring the absorbance of the colored
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products obtained after a hydrolysis reaction of alginate. The hydrolysis of alginate was
carried out in extreme conditions (10 N HCl, 5 h, 100 ◦C) and, after this reaction, samples
were neutralized with 10 N NaOH and cooled. Absorbance of the samples was measured
at 277.6 nm. A standard curve of alginate (0.5–4 mg/mL) was prepared. Concentration of
BSA in the supernatant was determined using Bradford’s method [20]. The absorbance of
blue-colored products of this reaction could be measured at 595 nm. To avoid interactions
between alginate and Bradford reagent, the BSA in the supernatant was precipitated with
2M trichloroacetic acid (TCA). After the precipitation process, samples were centrifuged
and the supernatant was removed. The pellet was suspended in 1 mL 6M urea (urea
solution in 2 N HCl). A standard curve of BSA (0.125–0.5 mg/mL) was prepared.
2.3.2. Thermogravimetric Analysis (TGA)
TGA curves of BSA/ALG nanoparticles, as well as raw materials, were obtained using
a Mettler Toledo thermal analyzer (TGA-SDTA 851®, Switzerland). Samples (3 mg) were
placed onto the balance, the temperature increased from 25 to 600 ◦C at 10 ◦C min−1 in
a nitrogen atmosphere (nitrogen flow rate of 60 cm3 min−1) and the mass continuously
recorded as a function of temperature.
2.3.3. Determination of Folate-Conjugated to BSA/ALG Nanoparticles
The amount of folate conjugated to the amine groups of albumin was determined
by spectrophotometric analysis [18]. A quantity of 2 mg folate-conjugated nanoparticles
(Nps–Fol) were hydrolysed by trypsin (0.05 mg/mg NP) with stirring at 37 ◦C for 2 h.
After the digestion process, the quantification of folate-conjugation was performed by spec-
trophotometric measurement of its absorbance at 358 nm (folic acid ε = 8643.5 M−1 cm−1).
2.3.4. Morphology, Size and Z-Potential of Nanoparticles
The morphology and size of Nps and Nps–Fol were studied by Transmission Electron
Microscopy (TEM) (JOEL JEM 1010 microscope from ICTS Centro Nacional de Microscopía
Electrónica, UCM). Size and zeta potential measurements of Nps and Nps–Fol were per-
formed in deionized distilled water using a backscattered quasi-elastic light scattering
device (Zetatrac NPA). Data were analyzed with Microtrac Flex Software.
2.3.5. Preparation of PTX–Folate-Conjugated Nanoparticles
The paclitaxel (PTX) load into Nps–Fol was carried out as follows: a suspension
of 30 mg of NPs–Fol in 1 mL of the solution 1 mg PTX/mL ethanol was prepared and
incubated for 22 h using a circular rotary stirrer in darkness at room temperature. Finally,
the suspension was centrifuged (12,000 rpm, 15 min), the pellet was washed with water
and nanoparticles were freeze-dried.
2.3.6. Estimation of PTX Content
Two different methods were carried out in order to determine the amount of PTX
loaded into Nps–Fol. One of the methods consisted of a direct extraction of the drug
from PTX-loaded Nps–Fol using ethanol: 3 mg of PTX-loaded Nps–Fol were suspended
in 1 mL of ethanol under stirring conditions for 5 h. After this time, the suspension was
centrifuged (13,000 rpm, 5 min) and the supernatant was collected. The samples were
analyzed by HPLC. The other method consisted of an enzymatic digestion of PTX-loaded
Nps–Fol with trypsin and a subsequent extraction of the drug with an organic solvent:
2 mg of PTX-loaded nanoparticles was suspended in 2 mL of phosphate-buffered saline
(PBS, pH 7.4), and 50 µg of trypsin was added to the solution. The digestion process was
performed under orbital stirring (100 rpm) at 37 ◦C for 24 h. After this time, PTX was
extracted from PBS solution by the addition of 4 mL of dichloromethane. The tubes were
mixed in a vortex mixer for 10 min and then centrifuged for 10 min at 10,000 rpm. The
organic phase was transferred to flask vials and evaporated to dryness. The resulting
residue was reconstituted in ethanol and then quantified by the HPLC technique.
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The concentration of PTX was determined by high-performance liquid chromatog-
raphy (HPLC) using a Spectra Physics HPLC system, Spectra 100 UV–Vis detector and
a SP8800 pump. The mobile phase consisted of acetonitrile/water 60:40 (v/v) and was
pumped through 25 mm × 4.6 mm RP-Spherisorb ODS2 C18 column (5 mm particle size,
Waters) at a flow rate of 1 mL/min. The output at 227 nm was monitored and the peak
area of each sample generated by ChromQuestTM software. The calibration curve was
generated using PTX solutions between 0.1 and 25 µg/mL in acetonitrile/water (60:40, v/v),
prepared from a PTX solution in ethanol, and a good linear correlation (r2 = 0.99) was
obtained. All quantifications were performed in triplicate.
2.3.7. In Vitro Drug Release Studies
The release of PTX from Nps–Fol was carried out in centrifuge tubes. Drug-loaded
Nps–Fol (3 mg) was suspended in PBS (4 mL pH 7.4, 37 ◦C) containing 0.1% (w/v) Tween
80® [21,22]. Release studies were carried out in the dark with orbital shaking (100 rpm;
Ecotron INFORS HT, Switzerland) for 96 h. Sink conditions were maintained during
drug release experiments and all experimental conditions were performed in triplicate.
At predetermined time intervals, the solutions were centrifuged at 10,000 rpm for 1 min
and the supernatants collected for PTX concentration analysis. The Nps–Fol samples
were dispersed in fresh PBS and placed back on the shaker. The PTX was extracted from
the supernatants by DCM (1 mL) by stirring using a vortex mixer for 10 min at room
temperature. The DCM layer collected was evaporated at room temperature for 24 h, and
the dried PTX was dissolved in acetonitrile/water (1 mL; 60:40 (v/v)). The percentage of
PTX released into the supernatant was determined by HPLC.
In order to analyze the drug delivery mechanism used by the NPs–Fol, the in vitro
drug release data were fitted to various kinetic models. Higuchi, Korsemeyer–Peppas,









Mo −Mt = Kot
First-order kinetic model
Mt/M∞ = 1 − e−Kt
where Mo, Mt and M∞ corresponded to the drug amount at time zero, at a particular time
and at an infinite time, respectively. The K terms referred to the release kinetic constants
obtained from the linear curves of simple regression analysis.
2.3.8. Cell Culture Studies
Human breast adenocarcinoma (MCF7, MDA-MB-231) and human cervical can-
cer HeLa cell lines were obtained from ECACC (Sigma-Aldrich).These cells were cho-
sen due to their expression of folate receptors (FRs) [24–26]. Cells were maintained in
DMEM + GlutaMax-I supplemented with 10% heat inactivated fetal bovine serum, peni-
cillin (50 U/mL), streptomycin (50 µg/mL) (Invitrogen Life Technologies, Grand Island,
NY, USA) and gentamicin (50 µg/mL) (Sigma–Aldrich Company, Gillingham, UK) in a hu-
midified incubator at 37 ◦C and 5% CO2 atmosphere (HERA cell, Sorval Heraeus, Kendro
Laboratory Products GmbH, Hanau, Germany). Cells were plated in a 75 cm2 flask (Sarst-
edt Ag and Co., Barcelona, Spain) and were passaged when they reached 90% confluence
by gentle trypsinization (0.05% trypsin/0.53 mM EDTA; Invitrogen Life Technologies).
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Cellular Uptake of Nanoparticles
Nps and Nps–Fol (10 mg) were loaded with 6-coumarin (98%, Sigma-Aldrich, Madrid,
Spain) by immersion in 1 mL of a 1 mg/mL 6-coumarin solution (dissolved in ethanol) for
24 h at room temperature in the dark and under orbital shaking. Then, the suspension was
centrifuged (7000 rpm, 5 min), and the 6-coumarin-loaded NPs were washed twice with
ethanol and freeze-dried for 24 h at −110 ◦C
Cellular uptake of Nps and Nps–Fol was investigated in a monolayer of MCF7, MDA-
MB-231 and HeLa cells. Cells were seeded in 96 well flat-bottom plates at 10,000 cells/well
for MCF7 and MDA-MB-231, and 5000 cells/well for HeLa. After 24 h, the medium was
replaced with 100 µL of 1% FBS medium containing 6-coumarin-loaded Nps or Np–Fol
and the plates were incubated in the 5% CO2 incubator at 37 ◦C for 2, 4 and 24 h. The
concentration of nanoparticles was the equivalent to obtain a concentration of 1 µM of
drug, considering the PTX load of each nanoparticle composition. Thus, the concentration
of 6-coumarin-loaded Nps and Nps–Fol was 0.24 mg/mL (composition 50BSA/50ALG)
and 0.325 mg/mL (composition 30BSA/70ALG) respectively. As a positive control, cells
were grown with 0.2 µg/mL of 6-coumarin in FBS medium, in the absence of nanoparticles.
At each time interval, cells were washed twice with PBS to remove any uninternalized
nanoparticles and lysed with 100 µL lysis reagent (PBS with 2% SDS v/v and 50 mM EDTA).
Internalization of nanoparticles was evaluated by fluorimetry at 488 nm, using a spectropho-
tometer (Varioskan, Thermo FisherScientific, Barcelona, Spain) [27]. Calibration curves
(fluorescence versus concentration) were prepared with 6-coumarin (1 ng/mL−1 µg/mL)
dissolved in the lysis medium in order to calculate the amount of 6-coumarin incorporated
into nanoparticles. All experimental conditions were performed in quintuplicate.
Fluorescence Microscopy
Cellular uptake of Nps and Nps–Fol with 6-coumarin was observed by fluorescence
microscopy. Cells were seeded in 24 well flat-bottom plates at 40,000 cells/well for MCF-7
and MDA-MB-231, and 20,000 cells/well for HeLa. After 24 h, the medium was replaced
with 500 µL of 1% FBS medium containing 6-coumarin-loaded Nps or Np–Fol and the
plates were incubated in the 5% CO2 incubator at 37 ◦C for 4 h. Then, cells were washed
twice with PBS to remove any uninternalized nanoparticles. Localization of Nps–Fol with
6-coumarin was examined by light fluorescence microscopy (Leica DMIL microscope, Leica
Microsystems, Balgach, Switzerland). Cells were photographed with a Leica DFC 300FX
digital camera and Leica Application Suite software was used for processing the pictures
(Leica Microsystems Switzerland).
Cell Viability
Cell viability was evaluated by using the MTT method. All experimental conditions
were performed in quintuplicate. Each experiment was carried out in triplicate.
In preliminary experiments, increasing concentrations of PTX from 0.1 to 500 nM were
tested in culture. The IC50 of PTX was determined in the three cell lines tested. According
to that, the selected concentrations of PTX in cell viability studies were 2.5 and 7.5 nM for
HeLa and MCF7 cell lines, and 7.5 and 30 nM for MDA-MB-231 cells.
Cells were seeded in 96-well flat-bottom plates at 5000 cells/well in the case of MCF7
and MDA-MB-231, and at 2500 cells/well in the case of HeLa. After 24 h, the medium was
replaced with 100 µL medium with 1% FBS containing Nps–Fol, PTX-loaded Nps–Fol or
the drug in solution. The amount of Nps–Fol was the needed to obtain a final concentration
of 30, 7.5 and 2.5 nM of PTX, considering the PTX load of each nanoparticle composition; for
this purpose, a nanoparticle suspension of 0.24 mg/mL of 50BSA/50ALG and 0.325 mg/mL
of 30BSA/70ALG Nps–Fol, (equivalent to 1000 nM PTX) was used. After 1, 3 and 6 days,
10 µL of MTT solution (5 mg/mL) were added to each well. After 2 h of incubation at 37 ◦C,
5% CO2, each well was replaced with 100 µL DMSO [24]. The cell viability was determined
by measuring the absorbance at 570 nm using a spectrophotometer (Varioskan, Thermo
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Fisher Scientific, Barcelona, Spain). Results are expressed as the percentage survival in
relation to untreated control cells.
2.4. Statistical Analysis
Statistical comparisons were performed with the unpaired Student’s t-test. A value of
p < 0.05 was considered significant.
3. Results
3.1. Preparation of BSA/ALG Nanoparticles
3.1.1. Composition of Nanoparticles
Final nanoparticle composition was determined by the concentration of BSA and ALG
in the supernatant collected after centrifugation, in the synthesis process. Thus, the contri-
bution of each polymer within the final formulation of nanoparticles was calculated by the
difference between the initial concentration and the final concentration after the synthesis
protocol (Table 1). The BSA/ALG ratio was calculated considering the concentration of
each polymer incorporated into nanoparticles. These results demonstrated that not all
the BSA nor ALG added in the initial solution of synthesis was incorporated in the final
nanoparticles. Surprisingly, an increased proportion of BSA (w/w) in the initial composition
was not translated into a higher incorporation of BSA into Nps.
Table 1. Nanoparticle composition. Percentage of each polymer incorporated into nanoparticles. BSA/ALG ratio in nanoparticles.







30BSA/70ALG 2BSA:1ALG 52 ± 4 65 ± 5 1/1
40BSA/60ALG 3BSA:1ALG 13 ± 4 50 ± 2 0.25/1
50BSA/50ALG 5BSA:1ALG 25 ± 3 54 ± 4 0.5/1
3.1.2. Thermogravimetric Analysis (TGA)
The thermal stability of raw materials and BSA/ALG nanoparticles was studied. The
TGA first derivative of the materials is plotted in Figure S1 (Supplementary Materials). The
Nps showed a thermal profile different from raw materials: Nps that included more BSA
in their composition (30BSA/70ALG, ratio 1:1) showed a two-step degradation process:
at 217 ◦C (close to the degradation peak of ALG) and 317 ◦C (close to the degradation
peak of BSA). However, Nps with more ALG in their composition (40BSA/60ALG, ratio
0.25:1; 50BSA/50ALG, ratio 0.5:1) showed only one degradation peak at 212 ◦C (close to the
degradation peak of ALG). These differences in thermal behavior between raw materials
and the Nps would indicate the chemical interaction between both polymers in the Nps
and would confirm the different ratio of polymers incorporated in each Np composition.
Additionally, all Np compositions showed a mass loss above 200 ◦C which indicated that
Nps were stable to use at routine work temperatures.
3.1.3. Determination of Folate Conjugated to Nanoparticles
The amount of folate conjugated to Nps–Fol was spectrophotometrically evaluated af-
ter the hydrolysis of nanoparticles by trypsin. Values of 30± 2, 9± 2 and 26 ± 2 µmol Fol/g
Nps were respectively obtained from 30BSA/70ALG–Fol, 40BSA/60ALG–Fol and 50BSA/
50ALG–Fol. Statistically significant differences did not exist between 30BSA/70ALG–Fol
and 50BSA/50ALG–Fol nanoparticles (p = 0.07) (data not shown); however, significant
differences were observed between 30BSA/70ALG–Fol and 40BSA/60ALG–Fol (p = 0.0002)
and also between 50BSA/50ALG–Fol and 40BSA/60ALG–Fol (p = 0.0004). Therefore, no
correlation between the amount of BSA in the nanoparticles and the extent of folate on
their surface was established.
According to these results, the compositions 30BSA/70ALG–Fol and 50BSA/50ALG–
Fol were finally chosen for further studies due to their greater content of incorporated folate.
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3.2. Characterization of Folate-Conjugated BSA/ALG Nanoparticles
3.2.1. Morphology, Size and Z-Potential of Nanoparticles
The morphology of 30BSA/70ALG and 50BSA/50ALG Nps was analyzed by TEM. Mi-
crographs showed nanometric-range sized particles (<100 nm), with a spherical appearance.
This morphology was maintained after folate conjugation (Figure 1).
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Figure 1. of 30BSA/ (A), 30BSA/70 (B), PTX-loaded
30BSA/70 L –Fol (C), 50BSA/50 L ( ), 50BSA/50 L –Fol (E) and PTX-loaded 50BSA/50 LG–
Fol (F) nanoparticles.
These nanoparticles were also analyzed using quasi-elastic light scat ering to charac-
terize them in terms of mean size and surface charge (Table 2). The results showed that all
synthesized systems had a nanometric size in the range of 169 ± 28 nm and 296 ± 57 nm
and a polydispersity index betwe n 1.2 ± 0.4 and 1.8 ± . . , an increase in size
was observed after the incorporation of folate and the loading of paclitaxel in both nanopar-
ticle compositions. However, these differences in size were not statistically significant.
Dif erences in nanoparticle size among TEM photographs and DLS data can be at ributed
to the dif erent characteristics of these techniques. In this ay, DLS measures are realized
in a water solution without stir ing, and nanoparticles tend to establish interactions and
aggregate, increasing the observed size.
Table 2. Mean size, polydispersity index and zeta potential of nanoparticles and folate-conjugate nanoparticles determined
by quasi-elastic light scattering. Data were shown as mean ± S.D.
Nanoparticles Mean Size (nm) Polydispersity Index Zeta Potential (mV)
30BSA/70ALG 182 ± 82 1.4 ± 0.7 −0.12 ± 0.04 a
30BSA/70ALG–Fol 189 ± 81 1.7 ± 0.3 −69.3 ± 0.8 a
PTX-loaded 30BSA/70ALG–Fol 290 ± 126 1.8 ± 0.4 −67.3 ± 0.8 a
50BSA/50ALG 169 ± 28 1.5 ± 0.3 −0.43 ± 0.06 b
50BSA/50ALG–Fol 268 ± 102 1.4 ± 0.3 −66.2± 0.6 bc
PTX-loaded 50BSA/50ALG–Fol 296 ± 57 1.2 ± 0.4 −94.1± 0.4 bc
a: significant statistical differences (p < 0.001) between 30BSA/70ALG y 30BSA/70ALG–Fol, and between 30BSA/70ALG and PTX-
loaded 30BSA/70ALG–Fol; b: significant statistical differences (p < 0.001) between 50BSA/50ALG y 50BSA/50ALG–Fol, and between
50BSA/50ALG and PTX-loaded 50BSA/50ALG–Fol; c: significant statistical differences (p < 0.001) between 50BSA/50ALG–Fol and
PTX-loaded 50BSA/50ALG–Fol.
Results of Z-potential analysis (Table 2) showed a negative charge at the surface of all
the tested compositions, like the results obtained in similar studies [28]. The negative value
of this parameter was increased after the conjugation of folic acid and the incorporation of
PTX in both formulations, those differences were statistically significant.
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3.2.2. Estimation of PTX Content in Folate-Conjugate Nanoparticles
The estimation of PTX content in each formulation was determined by two methods:
extraction with ethanol and enzymatic degradation using trypsin (Table 3). Independently
of the method, results showed statistically significant differences (p < 0.05) in drug content
comparing both compositions, showing a higher PTX load in 50BSA/50ALG–Fol nanoparticles.
Table 3. Estimation of PTX content in folate-conjugated nanoparticles (Nps–Fol).
Drug Content in Nps–Fol
Nanoparticles By Extraction with Ethanol(µg PTX/mg Np)
By Tryptic Hydrolysis of the Nanoparticles
(µg PTX/mg Np)
50BSA/50ALG–Fol 3.56 ± 0.13 a 3.28 ± 0.24 b
30BSA/70ALG–Fol 2.63 ± 0.19 a 2.42 ± 0.36 b
Data: mean ± S.D. (n = 3). a: significant statistical differences p < 0.05 (p = 0.002); b: significant statistical differences p < 0.05 (p = 0.03).
3.2.3. PTX Release from Folate-Conjugated Nanoparticles (Nps–Fol)
The cumulative release curve of PTX is represented in Figure 2. The maximum PTX
release (82% and 88% of drug load) was achieved at 23 and 27 h from 30BSA/70ALG–Fol
and 50BSA/50ALG–Fol, respectively. Drug release in the presence of Tween 80® oc-
curred quickly in the first 4 h (Table 4), followed by a slower release rate in both types
of nanosystem. In both stages of drug delivery, the release of PTX was faster from the
50BSA/50ALG–Fol composition.































Figure 2. Cumulative release of PTX from BSA/ALG–Fol nanoparticles. 
Table 4. Release rates of PTX from 50BSA/50ALG–Fol and 30BSA/70ALG–Fol nanoparticles. 
Nanoparticles 
Release Rate of PTX from Nanoparticle–Fol  
First Stage: 0–4 h  Second Stage: 5–27 h  
50BSA/50ALG–Fol 0.63 µg PTX/h per mg of Nps–Fol (r2 0.973) 
0.019 µg PTX/h per mg of Nps–Fol 
(r2 0.935) 
30BSA/70ALG–Fol 0.43 µg PTX/h per mg of Nps–Fol (r2 0.823) 
0.008 µg PTX/h per mg of Nps–Fol 
(r2 0.877) 
The PTX release was also evaluated in a Tween 80® free medium at 74 h. In this ex-
perimental condition, only 16% and 23% of the PTX load was released from 
50BSA/50ALG–Fol and 30BSA/70ALG–Fol, respectively. 
3.3. In Vitro Evaluation of Folate-Conjugated Nanoparticles in Tumour Cell Lines 
3.3.1. Cellular Uptake of Nanoparticles 
To evaluate the uptake of the synthesized nanosystems by cells, three different hu-
man tumor cell lines, MCF-7, MDA-MB-231 and HeLa, were selected. BSA/ALG–Fol na-
noparticles and BSA/ALG nanoparticles were loaded with a fluorescent marker (6-cou-
marin) and added to cells in order to study their cellular uptake. The fluorescent signal 
into cells was quantified after 2, 4 and 24 h of incubation. Results are shown in Figure 3. 
As results showed, either targeted or non-targeted systems were internalized in cells. 
However, folate-conjugated nanoparticles enhanced their uptake in the three cell lines. 
The 50BSA/50ALG nanoparticles were less internalized than 30BSA/70ALG. 
Figure 2. Cumulative r leas of PTX from BSA/ALG–Fol nanoparticles.
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Table 4. Release rates of PTX from 50BSA/50ALG–Fol and 30BSA/70ALG–Fol nanoparticles.
Nanoparticles
Release Rate of PTX from Nanoparticle–Fol
First Stage: 0–4 h Second Stage: 5–27 h
50BSA/50ALG–Fol 0.63 µg PTX/h per mg of Nps–Fol(r2 0.973)
0.019 µg PTX/h per mg of Nps–Fol
(r2 0.935)
30BSA/70ALG–Fol 0.43 µg PTX/h per mg of Nps–Fol(r2 0.823)
0.008 µg PTX/h per mg of Nps–Fol
(r2 0.877)
The PTX release was also evaluated in a Tween 80® free medium at 74 h. In this experi-
mental condition, only 16% and 23% of the PTX load was released from 50BSA/50ALG–Fol
and 30BSA/70ALG–Fol, respectively.
3.3. In Vitro Evaluation of Folate-Conjugated Nanoparticles in Tumour Cell Lines
3.3.1. Cellular Uptake of Nanoparticles
To evaluate the uptake of the synthesized nanosystems by cells, three different human
tumor cell lines, MCF-7, MDA-MB-231 and HeLa, were selected. BSA/ALG–Fol nanopar-
ticles and BSA/ALG nanoparticles were loaded with a fluorescent marker (6-coumarin)
and added to cells in order to study their cellular uptake. The fluorescent signal into cells
was quantified after 2, 4 and 24 h of incubation. Results are shown in Figure 3. As results
showed, either targeted or non-targeted systems were internalized in cells. However, folate-
conjugated nanoparticles enhanced their uptake in the three cell lines. The 50BSA/50ALG
nanoparticles were less internalized than 30BSA/70ALG.
Besides the quantitative assay, the internalization of these systems was easily observed
due to the green fluorescence of coumarin attached to the particles. Figure 3 shows the
uptake when they were functionalized with folate (BSA50/50ALG–Fol) for 4 h, as an
example of the images obtained.
3.3.2. Cell Viability
Tumor cell cytotoxicity induced by different concentrations of unloaded and PTX-
loaded BSA/ALG–Fol nanoparticles was determined in MCF7, MDA-MB-231 and HeLa
cells. IC50 values of PTX in solution were 7.32 nM, 7.71 nM and 38 nM for HeLa, MCF7
and MDA-MB-231 cells, respectively, after 24 h of incubation. According to these results,
two concentrations of PTX (2.5 and 7.5 nM for the HeLa and MCF7 cell lines, and 7.5 and
30 nM for the MDA-MB-231 cell line) were selected to perform cell viability studies. Cell
viability studies in the presence of unloaded and PTX-loaded 50BSA/50ALG–Fol and
30BSA/70ALG–Fol nanoparticles were carried out over one, three and six days using the
equivalent concentration to 2.5 and 7.5 nM PTX for HeLa and MCF7 cell lines, and 7.5 and
30 nM PTX for the MDA-MB-231 cell line when the drug was administered by nanoparticles.




Figure 3. Quantitative comparison of coumarin-loaded internalized nanoparticles in (a) MCF-7, (b) MDA-MB-231 and (c) 
HeLa cells. Fluorescence microscopy images of coumarin-loaded internalized nanoparticles 50BSA/50ALG–Fol into MCF-
7 (d), MDA-MB-231 (e) and HeLa (f) after 4 h of incubation. 
Besides the quantitative assay, the internalization of these systems was easily ob-
served due to the green fluorescence of coumarin attached to the particles. Figure 3 shows 
the uptake when they were functionalized with folate (BSA50/50ALG–Fol) for 4 h, as an 
example of the images obtained. 
3.3.2. Cell Viability 
Tumor cell cytotoxicity induced by different concentrations of unloaded and PTX-
loaded BSA/ALG–Fol nanoparticles was determined in MCF7, MDA-MB-231 and HeLa 
cells. IC50 values of PTX in solution were 7.32 nM, 7.71 nM and 38 nM for HeLa, MCF7 
and MDA-MB-231 cells, respectively, after 24 h of incubation. According to these results, 
two concentrations of PTX (2.5 and 7.5 nM for the HeLa and MCF7 cell lines, and 7.5 and 
30 nM for the MDA-MB-231 cell line) were selected to perform cell viability studies. Cell 
viability studies in the presence of unloaded and PTX-loaded 50BSA/50ALG–Fol and 
30BSA/70ALG–Fol nanoparticles were carried out over one, three and six days using the 
equivalent concentration to 2.5 and 7.5 nM PTX for HeLa and MCF7 cell lines, and 7.5 and 
30 nM PTX for the MDA-MB-231 cell line when the drug was administered by nanoparti-
cles. 
Figure 3. Quantitative comparison of coumarin-loaded internalized nanoparticles in (a) MCF-7, (b) MDA-MB-231 and (c)
HeLa cells. Fluorescence microscopy images of coumarin-loaded internalized nanoparticles 50BSA/50ALG–Fol into MCF-7
(d), MDA-MB-231 (e) and HeLa (f) after 4 h of incubation.
Both unloaded nanoparticles (50BSA/50ALG–Fol and 30BSA/70ALG–Fol) were cy-
tocompatible and no significant decrease in viability (cell survival between 91% ± 6%
and 89% ± 3% for MCF7; 83% ± 5% and 84% ± 13% for MDA-MB-231; 100% ± 3%
and 100% ± 12% for HeLa) was observed for the three tested cell lines at longer times
of exposure.
PTX administered into 50BSA/50ALG–Fol and 30BSA/70ALG–Fol nanoparticles
(Figure 4) caused a more gradual decrease in cell viability than PTX in solution from the
first day, at the highest drug concentration assayed for MCF7, MDA- B-231 and HeLa cells.
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Figure 4. Cell viability of MCF-7, MDA-MB-231 and HeLa cells in the presence of paclitaxel (PTX) in solution and
PTX-loaded nanoparticles.
4. Discussion
Paclitaxel (PTX) is one of the most common drugs used for the treatment of different
types of solid tumors [16]. PTX acts by promoting microtubule polymerization by binding
to the β-subunit of tubulins, which causes mitotic arrest at the G2/M phase and results in
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cell death by the apoptosis pathway. Besides this, PTX exhibits cytotoxic properties that
lead to the inhibition of cellular growth. Both characteristics contribute to the antitumor
efficacy of PTX [29]. Since it is a hydrophobic drug, a vehicle is required to dissolve it, which
causes numerous side effects, limiting its optimal clinical utility as an anticancer agent.
For this reason, different nanocarriers have been prepared to improve the safety, efficacy
and pharmacokinetic profile of PTX. Thus, in recent studies PTX has been encapsulated
in nanoparticles [30,31], liposomes [32] and polymeric micelles [33]. On the other hand,
the folate receptor is overexpressed on many tumors [34]. The FRα isoform is the most
widely expressed of all the FR isoforms [35] and is overexpressed (100–300 times more than
in healthy cells) in a large number of cancers of epithelial origin. Besides this, the high
binding affinity (KD = 0.1–1 nM) [36] of FRα for folic acid and other oxidized folates has led
to the development of folate-conjugated nanosystems for targeting cancer cells [37,38]. For
these reasons, folic acid was selected to target tumor cells with folate-bounded drug-loaded
BSA/ALG nanoparticles.
4.1. Composition, Characterization and PTX Release from Folate-Conjugated Nanoparticles
Nanoparticles of different BSA/ALG composition, cross-linked with ethylenediamine
(ED), were synthesized. BSA was better incorporated in 30BSA/70ALG (BSA:ALG 1:1)
nanoparticles; meanwhile, alginate was similarly incorporated in all compositions, which
can be attributed, at least in part, to the formation of amide bonds between ED and
carboxylic groups of both ALG and BSA (each BSA molecule has 58 residues of Glu and
41 residues of Asp). TGA results confirmed the different ratio of polymers incorporated
in each Np composition and could also indicate the chemical interaction between both
polymers in Np.
Covalent attachment of folic acid to the three systems was achieved. There was no
correlation between the amount of BSA in the nanoparticles and the extent of folate on
their surface. Whereas 30BSA/70ALG–Fol and 50BSA/50ALG–Fol nanoparticles bound a
similar amount of folic acid (FA), 40BSA/60ALG–Fol nanoparticles showed a significantly
lower amount of FA attached. This fact could be related to the disposition of the amine
groups of the side chain of amino acids in the nanoparticles; one BSA molecule has
60 residues of Lys and 26 residues of Arg, which can participate in FA attaching. Thus, the
low amount of FA attached was the main reason to reject 40BSA/60ALG–Fol nanoparticles
for later experiments.
TEM micrographs showed spherical, nano-sized particles without significant dif-
ferences between nanoparticles of different BSA/ALG composition or those that were
FA-bounded and not. The size of the unloaded nanosystems, determined by DLS (Table 2),
was larger, but not statistically significantly so, for 50BSA/50ALG–Fol (268 ± 102 nm)
than for 30BSA/70ALG–Fol (189 ± 81 nm), which could be due to the larger proportion of
alginate in those nanoparticles, which would induce a higher swelling of the systems. How-
ever, the value of the polydispersity index was the same for both types of nanoparticles,
and it was like the values obtained for other polymeric systems [12,39].
The Z-potential value of all studied nanosystems was negative (Table 2). The presence
of alginate in 30BSA/70AGL and 50BSA/50ALG nanoparticles showed lightly negative
Z-potential values. The FA-bounded nanosystems significantly increased Z-potential
values (−69.3 mV and −66.2 mV for 30BSA/70ALG–Fol and 50BSA/50ALG–Fol, respec-
tively), which were very much larger than −30 mV, the Z-potential value (positive or
negative value) that has been established as the minimum for obtaining a physically sta-
ble nanosuspension and avoiding nanoparticle aggregation [40]. Besides this, when these
nanosystems were loaded with PTX, Z-potential was of the same magnitude for PTX-loaded
30BSA/70ALG–Fol, and significantly larger (−94.1 mV) for PTX-loaded 50BSA/50ALG–
Fol. This increase could be explained by the possible superficial distribution of part of
the drug on the nanosystem. Thus, the low tendency to establish interactions among
them, indicated by the Z-potential value of these unloaded and PTX-loaded FA-attached
nanosystems, make them very suitable for later in vivo intravenous administration studies.
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The PTX load of Fol-nanosystems was determined by extraction with ethanol and
afterward by the enzymatic digestion of the nanoparticles with trypsin (Table 3). No
differences were observed among the results obtained by both methods. Regardless of
the method used, the PTX load of 50BSA/50ALG–Fol was larger (3.56–3.28 µg PTX/mg
Np) than that of 30BSA/70ALG–Fol (2.63–2.42 µg PTX/mg Np). Interactions between
PTX and nanosystems seem to be very similar in both types of nanoparticles since the
value of the PTX load obtained by the two methods is almost the same. These observed
results were in contrast with the expected results, where the drug load determined by
ethanol extraction should be lower than that obtained by enzymatic digestion in the case
of high PTX–nanoparticle interaction [24]. The PTX release studies showed a prolonged
and faster drug release from 50BSA/50ALG–Fol nanoparticles; PTX release took place in
two stages from both types of nanosystems (Figure 3). The first stage of release was during
the first four hours (Table 4), and the release was faster from 50BSA/50ALG–Fol, which
could be related to a part of the drug being located more superficially as indicated by the
Z-potential values. A second stage of drug release was determined up to 27 h, and PTX
release was faster from 50BSA/50ALG–Fol. In no case was the total amount of the PTX
load released: 88% of the PTX load was released from 50BSA/50ALG–Fol and 82% of it
from 30BSA/70ALG–Fol. In all these experiments, the release conditions were favored
by the presence of Tween 80® in the medium; however, in the absence of the surfactant,
an experimental condition closer to biological systems, a slower release occurred, which
would make possible a significant amount of PTX loaded into the nanoparticle–Fol to
be delivered to cancer cells in vivo. Similar in vitro PTX release behavior was observed
when that drug was released from nanohydrogels [27]. In that case, a maximum release
took place at 50 h, and it caused a significant decrease in cell viability of human cancer
cell lines. These PTX-loaded nanoparticulated systems were subcutaneously injected in
female athymic nude mice bearing HeLa human tumor xenografts, and they showed higher
antitumor activity than PTX in solution [41]. Equivalently, tamoxifen-loaded folate-targeted
protein/polysaccharide-based nanoparticles, which released the drug in the first 8 h in
in vitro studies, were demonstrated to be highly effective in tumor remission assays in
MCF7 cell xenograft mice after intravenous administration [24]. In that case, although
in vitro drug release from nanoparticulated and folate-targeted nanoparticulated systems
took place faster, the results obtained in xenograft models demonstrated the effectiveness
of these types of nanosystems as an antitumoral therapy.
In order to determine the predominant drug release mechanism from BSA/ALG–Fol
nanoparticles, the obtained data were fitted to different physical models with a significant
correlation coefficient (r2 = 0.791–0.979) (Supplementary Materials; Table S2). According
to the results, the PTX release kinetics from 50BSA/50ALG–Fol nanoparticles fitted in the
order of Korsemeyer–Peppas = Higuchi = First Order > Zero Order; PTX release from
30BSA/70ALG–Fol nanoparticles fitted in the order of Korsemeyer–Peppas > Higuchi >
First Order > Zero Order. The Higuchi model indicates drug diffusion from the matrix,
with no matrix dissolution and constant drug diffusivity [42]. The release of PTX from
30BSA/70ALG–Fol nanoparticles showed the lowest value of KH, which implies a slower
release in comparison with 50BSA/50ALG–Fol nanoparticles. An equivalent behavior has
been observed for the release of naproxen from cyclodextrin-based hydrogel matrices [43].
The release of PTX was favored by the swelling capability of the nanoparticles, which
made the diffusion of the entrapped drug easier. In the case of the Korsemeyer–Peppas
model, the nanosystems showed values of the release exponent (n) different from the
standard value for declaring Fickian release behavior (n = 0.43; considering spherical
shape) [44,45]. This was 0.36 and 0.70 for 30BSA/70ALG–Fol and 50BSA/50ALG–Fol
nanoparticles, respectively. The values of the n parameter lower than 0.43 can be related
to a dispersion of nanoparticle sizes. For spherical particles, when the n value is between
0.43 and 0.85, an anomalous transport (non-Fickian; intermediate between Fickian and
Case II transport, zero order) is considered, and then a mixed diffusion and chain relaxation
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mechanism takes place, which happened for PTX release from 50BSA/50ALG–Fol. This
nanoparticle composition presents an acceptable fitting to the first order kinetic model.
4.2. In Vitro Evaluation of Folate-Conjugated Nanoparticles in Tumor Cell Lines
The presence of FRs in several human solid tumors, such as breast cancer, has been
clearly demonstrated. Thus, these receptors provide an interesting therapeutic target for
solid tumor treatment. PTX is widely used as a first-line treatment for patients with breast
cancer [25]. The cancer cell lines of human breast adenocarcinoma MCF-7 and MDA-MB-
231 express a low and high level of folate receptor, respectively [46]. However, whereas
MCF-7 cells express estrogen receptors (ER), MDA-MB-231 cells are triple negative breast
cancer (TNBC) cells; they do not express ER, progesterone receptor (PR) or the amplification
of HER-2/Neu [47]. Besides this, among the drugs used to treat stage IVB cervical cancer
is PTX [48]. HeLa cells are human cervical carcinoma cells, positive for FR, adequate to
study the efficacy of these folate-targeted PTX-loaded BSA/ALG nanocarriers.
Therefore, these three different cellular lines expressing folate receptors (FRs) were
chosen for evaluating the effectiveness of these BSA/ALG–Fol nanoparticles. Different
studies carried out by our group [24] and other research [49] have shown that MCF7, MDA-
MB-231 and HeLa cells express different levels of FRs on their surface, meaning they can
be used as an in vitro test of folate-targeted nanosystem efficacy. In general, good cytocom-
patibility values were obtained with the two compositions of BSA/ALG–Fol nanoparticles
for the three cell lines, although a slightly lower value was observed for MDA-MB-231
cells, which can be attributed to the larger amount of nanoparticles in the experiments with
this cell line. Therefore, the uptake of unloaded nanoparticle–Fol observed in these cell
lines seemed not to be harmful even after six days of incubation. The presence of FRs on
the cell surface led to a larger uptake in these cell lines for both nanoparticle–Fol composi-
tions in comparison with the corresponding nanoparticle composition without folic acid
bounded on their surface. A larger amount of folate receptors on the cell surface made
nanoparticle–Fol uptake easier as fluorescence images of HeLa cells showed. The uptake
of Nps without FA on their surface revealed there was a nonspecific uptake mechanism
that would act in addition to FR-mediated internalization. In this way, different studies in-
dicate that negative-charged nanoparticles showed high cellular uptake due to electrostatic
interactions established with some parts of the cellular membrane [24,50], which would be
in accordance with the negative values of the Z-potential of these BSA/ALG nanoparticles.
This nonspecific uptake was lower in the case of 50BSA/50ALG nanoparticles in the three
cell lines studied, and so they would be less internalized into cells without FR on their
surface, like non-cancer cells.
PTX-loaded nanoparticle–Fol caused a gradual decrease in cell viability values when
PTX was released from both nanosystems, mainly at a higher PTX load (7.5 nM PTX for
MCF7 and HeLa; 30 nM for MDA-MB-231) at a longer time of incubation. Significant
differences in decreasing viability were not observed between PTX-loaded 50BSA/50ALG–
Fol and 30BSA/70ALG–Fol nanoparticles in all cell lines studied. Although viability values
obtained in the presence of PTX-loaded nanoparticle–Fol were similar to those of PTX in
solution, it must be taken into account that the PTX amount within the cells treated with
PTX-loaded nanosystems–Fol will be lower than the amount of drug available in cells
treated with PTX solutions, in accordance with in vitro drug release studies. Once PTX-
loaded nanoparticle–Fol was taken up into cells via the FR-mediated endocytosis pathway,
the unligate FR may then recycle to the cell surface at a rate in the range of 0.5–5 h [51]. It is
believed that more nanoparticles were taken up into the cells; PTX release would have take
place mainly after the enzymatic degradation of nanoparticles, which would have caused a
delay in the cytotoxic action of PTX-loaded nanoparticle–Fol compared to PTX in solution.
5. Conclusions
The prepared folate-targeted PTX–BSA/ALG nanoparticles seem to be a promising
alternative to the conventional use of Cremophor® EL and would reduce the drug re-
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sistance problem mediated by P-gp. Preliminary cellular assays have demonstrated the
effectiveness of these nanosystems against cancer cells overexpressing surface folate re-
ceptors. In this respect, a reduction in cell survival was observed in a cervical carcinoma
cell line, a breast adenocarcinoma ER+ cell line and a TNBC cell line, which causes a very
aggressive cancer type with a difficult treatment. These results allow us to think that the
synthesized folate-targeted PTX–BSA/ALG nanoparticles could be considered for further
in vivo biocompatibility and tumor growth suppression studies.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/polym13132083/s1, Figure S1: TGA first derivative curves of BSA, sodium alginate, 30BSA/
70ALG Nps, 40BSA/60ALG Nps and 50BSA/50ALG Nps; Table S1: Percentages (v/v) of BSA
(5% w/v) and ALG (1% w/v) solutions added to each blend; Table S2. Statistical parameters of
nanoparticle formulations obtained after fitting the drug release data to the release kinetic models.
Model fitting was attempted until 91% and 85% of drug released for PTX-30BSA/70ALG-Fol and
PTX-50BSA/50ALG-Fol, respectively.
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